Novo Nordisk was previously sued in 2023, along with competitor Eli Lilly, by a patient with severe gastrointestinal side effects after taking Ozempic and Lily's Mounjaro.

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and peripheral artery disease (PAD), potentially adding yet another ...